{"id":"cggv:3cc2a1ae-5f3d-445c-b124-f3d38fdd070av1.1","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:3cc2a1ae-5f3d-445c-b124-f3d38fdd070a_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10025","date":"2021-01-08T19:29:39.787Z","role":"Publisher"},{"id":"cggv:3cc2a1ae-5f3d-445c-b124-f3d38fdd070a_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10025","date":"2018-09-25T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"cggv:3cc2a1ae-5f3d-445c-b124-f3d38fdd070a_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:3cc2a1ae-5f3d-445c-b124-f3d38fdd070a_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:95686359-7873-469b-bfde-4ea02029089e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c634ddef-be2d-46bb-9a47-0c26cbb21f83","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"The authors examined the expression of each calmodulin gene in human heart (left ventricle) from three developmental stages (fetal, infant, adult) using quantitative RT-PCR and gene-specific fluorogenic TaqMan probes. All calmodulin genes are expressed throughout development with the rank order of expression being CALM3 > CALM2 >CALM1","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26969752","type":"dc:BibliographicResource","dc:abstract":"Calmodulin (CaM) is encoded by 3 genes, CALM1, CALM2, and CALM3, all of which harbor pathogenic variants linked to long QT syndrome (LQTS) with early and severe expressivity. These LQTS-causative variants reduce CaM affinity to Ca(2+) and alter the properties of the cardiac L-type calcium channel (CaV1.2). CaM also modulates NaV1.5 and the ryanodine receptor, RyR2. All these interactions may play a role in disease pathogenesis. Here, we determine the spectrum and prevalence of pathogenic CaM variants in a cohort of genetically elusive LQTS, and functionally characterize the novel variants.","dc:creator":"Boczek NJ","dc:date":"2016","dc:title":"Spectrum and Prevalence of CALM1-, CALM2-, and CALM3-Encoded Calmodulin Variants in Long QT Syndrome and Functional Characterization of a Novel Long QT Syndrome-Associated Calmodulin Missense Variant, E141G."},"rdfs:label":"CALM genes in cardiomyocytes"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:0148ad38-735e-4cfa-ac82-274c21296d78","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:a886a231-055b-4c76-8b3c-338a98ef899b","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"RT-PCT of control samples (origin of samples not detailed)","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23388215","type":"dc:BibliographicResource","dc:abstract":"Life-threatening disorders of heart rhythm may arise during infancy and can result in the sudden and tragic death of a child. We performed exome sequencing on 2 unrelated infants presenting with recurrent cardiac arrest to discover a genetic cause.","dc:creator":"Crotti L","dc:date":"2013","dc:title":"Calmodulin mutations associated with recurrent cardiac arrest in infants."},"rdfs:label":"RT-PCR"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:b9fb4852-1c05-4512-b900-5864976f1ad9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:48ed4abc-23dc-4ce4-a9c8-c71fc039f7ce","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"Robust evidence for association of KCNQ1 with LQTS","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/16556865","type":"dc:BibliographicResource","dc:abstract":"The slow IKS K+ channel plays a major role in repolarizing the cardiac action potential and consists of the assembly of KCNQ1 and KCNE1 subunits. Mutations in either KCNQ1 or KCNE1 genes produce the long-QT syndrome, a life-threatening ventricular arrhythmia. Here, we show that long-QT mutations located in the KCNQ1 C terminus impair calmodulin (CaM) binding, which affects both channel gating and assembly. The mutations produce a voltage-dependent macroscopic inactivation and dramatically alter channel assembly. KCNE1 forms a ternary complex with wild-type KCNQ1 and Ca(2+)-CaM that prevents inactivation, facilitates channel assembly, and mediates a Ca(2+)-sensitive increase of IKS-current, with a considerable Ca(2+)-dependent left-shift of the voltage-dependence of activation. Coexpression of KCNQ1 or IKS channels with a Ca(2+)-insensitive CaM mutant markedly suppresses the currents and produces a right shift in the voltage-dependence of channel activation. KCNE1 association to KCNQ1 long-QT mutants significantly improves mutant channel expression and prevents macroscopic inactivation. However, the marked right shift in channel activation and the subsequent decrease in current amplitude cannot restore normal levels of IKS channel activity. Our data indicate that in healthy individuals, CaM binding to KCNQ1 is essential for correct channel folding and assembly and for conferring Ca(2+)-sensitive IKS-current stimulation, which increases the cardiac repolarization reserve and hence prevents the risk of ventricular arrhythmias.","dc:creator":"Shamgar L","dc:date":"2006","dc:title":"Calmodulin is essential for cardiac IKS channel gating and assembly: impaired function in long-QT mutations."},"rdfs:label":"Multiple"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.5},{"id":"cggv:3cc2a1ae-5f3d-445c-b124-f3d38fdd070a_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:3cc2a1ae-5f3d-445c-b124-f3d38fdd070a_cc_el","type":"EvidenceLine","evidence":[{"id":"cggv:ee549ca9-2b88-47ed-b50a-bc86ac245e6a","type":"EvidenceLine","evidence":[{"id":"cggv:ee549ca9-2b88-47ed-b50a-bc86ac245e6a_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:22e86a58-7f17-474e-80c2-a8339a5c013a","type":"Cohort","allGenotypedSequenced":39,"alleleFrequency":0,"detectionMethod":"Exome sequencing, analysis focused on CALM genes, confirmation of variants by sanger sequencing","evidence":[{"id":"cggv:ee549ca9-2b88-47ed-b50a-bc86ac245e6a_cc_evidence_item"}],"numWithVariant":0,"relatedCondition":{"id":"obo:MONDO_0002442"}},"controlCohort":{"id":"cggv:ddc2ed69-c89d-4090-bd3a-04d1abc03ef5","type":"Cohort","allGenotypedSequenced":60706,"alleleFrequency":0.0003788752347379172,"evidence":[{"id":"cggv:ee549ca9-2b88-47ed-b50a-bc86ac245e6a_cc_evidence_item"}],"numWithVariant":23},"method":{"id":"cg:AggregateVariantAnalysis"},"statisticalSignificanceType":"","statisticalSignificanceValueType":"Odds Ratio","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26969752","rdfs:label":"39 LQTS cases, mayo clinic"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":0,"dc:description":"No CALM3 mutations have been found in this study"}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":0},{"id":"cggv:3cc2a1ae-5f3d-445c-b124-f3d38fdd070a_ad_other_el","type":"EvidenceLine","evidence":[{"id":"cggv:8381f6a5-9a36-4005-94de-3a776efc7e82_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:f5c8273f-4aab-4c12-baae-45c5b85e03eb","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":3,"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Clinical genetic testing Negative for KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:8381f6a5-9a36-4005-94de-3a776efc7e82_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:b3b36da0-52aa-49bc-a1e1-b59466883999","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005184.4(CALM3):c.286G>C (p.Asp96His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16616292"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28491681","type":"dc:BibliographicResource","dc:creator":"Chaix MA","dc:date":"2016","dc:title":"Novel CALM3 mutations in pediatric long QT syndrome patients support a CALM3-specific calmodulinopathy."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28491681","rdfs:label":"02"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1.5,"dc:description":"Very likely to be de-novo"}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":1.5},{"id":"cggv:3cc2a1ae-5f3d-445c-b124-f3d38fdd070a_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"cggv:3ea91da2-b7fe-4305-b06d-4ec769d61932_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:27dcd757-10e0-4eaf-8bf0-66d7e1487293","type":"Proband","sex":"UnknownEthnicity","variant":{"id":"cggv:3ea91da2-b7fe-4305-b06d-4ec769d61932_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:57a2452d-4c50-4207-8f3a-5456a3f873bf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005184.4(CALM3):c.281A>C (p.Asp94Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16616071"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31170290","type":"dc:BibliographicResource","dc:abstract":"Calmodulinopathies are rare life-threatening arrhythmia syndromes which affect mostly young individuals and are, caused by mutations in any of the three genes (CALM 1-3) that encode identical calmodulin proteins. We established the International Calmodulinopathy Registry (ICalmR) to understand the natural history, clinical features, and response to therapy of patients with a CALM-mediated arrhythmia syndrome.","dc:creator":"Crotti L","dc:date":"2019","dc:title":"Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290","rdfs:label":"1"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:6d0ac50c-b878-44a8-8986-02009ea0f7b0_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:54dec177-845f-48d0-9ea0-b3cc76b4c823","type":"Proband","sex":"UnknownEthnicity","variant":{"id":"cggv:6d0ac50c-b878-44a8-8986-02009ea0f7b0_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:b3b36da0-52aa-49bc-a1e1-b59466883999"},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290","rdfs:label":"3"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:a67145d8-ed17-4638-9cb3-c3d468702ed3_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:1c4b38c5-e836-4e46-b316-d739f44644f9","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Clinical testing gene (-) for KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:a67145d8-ed17-4638-9cb3-c3d468702ed3_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:af0498a4-65c8-4b2c-bd57-159fb138365b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006888.6(CALM1):c.424T>C (p.Phe142Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA390690445"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28491681"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28491681","rdfs:label":"01"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:0a2359c8-e097-4755-8b5d-8ad261bb64c3_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:a8a4d589-bba8-4702-8cac-7d8e7fcfe54d","type":"Proband","sex":"UnknownEthnicity","variant":{"id":"cggv:0a2359c8-e097-4755-8b5d-8ad261bb64c3_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:25df5b6e-1f6a-4b22-895e-525901d01362","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005184.4(CALM3):c.421G>A (p.Glu141Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/812678"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290","rdfs:label":"5"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:475bb2ca-f2c8-467f-9498-6150bade81ae_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:f4344a49-59aa-47cd-b315-3441d8403b15","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"WES + filtering based on trio-study & prioritization using LQTS-related gene network","ethnicity":{"id":"cg:HispanicOrLatino"},"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Negative fr clinical LQTS panel (AKAP9, ANK2, CACNA1C, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, SCN4B, SCN5A, and SNTA)","sex":"Male","variant":{"id":"cggv:475bb2ca-f2c8-467f-9498-6150bade81ae_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:b4af1dd5-1f88-46be-9b99-99e1717561b2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006888.6(CALM1):c.389A>G (p.Asp130Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA186013"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/25460178","type":"dc:BibliographicResource","dc:creator":"Reed GJ","dc:date":"2015","dc:title":"CALM3 mutation associated with long QT syndrome."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25460178","rdfs:label":"01"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:484d974b-2e91-4a4d-91cf-e04f30cfcb00_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:f8fb3b4e-e203-407f-ba12-6083860033f8","type":"Proband","sex":"UnknownEthnicity","variant":{"id":"cggv:484d974b-2e91-4a4d-91cf-e04f30cfcb00_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:b3b36da0-52aa-49bc-a1e1-b59466883999"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290","rdfs:label":"2"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":12}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":1793,"specifiedBy":"GeneValidityCriteria7","strengthScore":13.5,"subject":{"id":"cggv:a414c8fb-8c9d-4707-b2b8-f08c21b8cda6","type":"GeneValidityProposition","disease":"obo:MONDO_0002442","gene":"hgnc:1449","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","dc:description":"Calmodulin is a calcium-binding protein that is essential for multiple intracellular processes including modulation of cardiac ion channels. An exactly identical calmodulin protein is encoded by 3 separate genes, CALM1-3, located on different chromosomes (14, 2 and 19, respectively). \nIn 2013 Crotti et al. were the first to identify de-novo missense variants in CALM1 and CALM2 in 2 patients with a unique phenotype (PMID 23388215). Both were infants presenting with marked QT prolongation, life-threatening ventricular arrhythmias and intermittent AV block. Subsequent studies identified multiple similar cases with de-novo variants in one of the 3 CALM genes. Based on this evidence the Expert Panel classified all calmoudulin genes (CALM1-3) as having a 'Definitive' level of evidence for disease causation of LQTS with atypical features presenting in childhood. \nNote: All LQTS genes were curated by 3 separate blinded teams. The evidence and scores reached by these 3 teams were reviewed by the LQTS Clinical Domain Expert Panel. For a detailed discussion of this group's work and the separate scores of the 3 teams please see \"Adler et al. An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation 2020;141(6):418-428. doi: 10.1161/CIRCULATIONAHA.119.043132‚Äù\nGenetic evidence over time","dc:isVersionOf":{"id":"cggv:3cc2a1ae-5f3d-445c-b124-f3d38fdd070a"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}